Last reviewed: June 25, 2026
Last updated: June 25, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
People with Type 1 diabetes face unique challenges when pursuing weight loss, since their bodies require insulin therapy regardless of weight changes. Recent clinical evidence suggests that GLP-1 receptor agonists like semaglutide can reduce appetite and support weight management in this population, though careful coordination with endocrinology care remains essential.
How Semaglutide Works in Type 1 Diabetes
Semaglutide activates GLP-1 receptors in the brain and gut, slowing gastric emptying and increasing satiety signals that reduce overall food intake. In Type 1 diabetes, this appetite suppression can help people achieve caloric deficits needed for weight loss while their basal insulin remains stable. The medication does not replace insulin or improve pancreatic function—it works as an adjunct tool to manage weight-related metabolic stress.
Unlike medications that lower blood sugar directly, semaglutide's primary role in Type 1 diabetes is reducing appetite and body weight, which in turn may reduce daily insulin requirements. Studies show that people with Type 1 diabetes using GLP-1 therapy experience modest reductions in total daily insulin doses, lower HbA1c variability, and improved time-in-range metrics. This secondary benefit occurs because less excess weight means improved insulin sensitivity at the tissue level.
Clinical Evidence for Type 1 Diabetes Weight Management
A 2022 retrospective analysis of people with Type 1 diabetes using GLP-1 receptor agonists found average weight losses of 8–15 pounds over 6 months, with concurrent reductions in insulin dosing of 10–20 percent. Importantly, HbA1c levels remained stable or improved in most participants, indicating that weight loss did not compromise glycemic control. These outcomes suggest that semaglutide can be a safe addition to existing insulin regimens when monitored appropriately.
Long-term data from observational cohorts demonstrate sustained weight management and improved metabolic markers in Type 1 diabetes patients on GLP-1 therapy beyond 12 months. Participants reported lower hypoglycemia frequency as insulin requirements decreased, and many experienced reduced insulin injection burden due to lower total daily doses. This evidence supports the use of semaglutide alongside insulin as part of a comprehensive weight management strategy.
Safety Considerations and Insulin Dose Adjustment
The most critical safety issue when starting semaglutide in Type 1 diabetes is hypoglycemia risk as appetite suppression reduces caloric intake and body weight improves insulin sensitivity. People must work closely with their endocrinologist to reduce basal and bolus insulin doses proactively—waiting for low blood sugar episodes to occur is dangerous and unnecessary. PlexusDx recommends ongoing communication between your primary care provider and diabetes specialist to coordinate dose adjustments as weight decreases.
Gastrointestinal side effects including nausea, vomiting, and constipation occur in 20–30 percent of semaglutide users and may complicate diabetes management by affecting meal timing and blood sugar predictability. These effects typically diminish within 4–8 weeks as the body adapts, but they can temporarily increase hypoglycemia risk if food intake becomes erratic. Starting at lower doses and titrating gradually minimizes GI side effects and allows insulin schedules to be adjusted systematically.
PlexusDx Semaglutide Injection for Type 1 Diabetes
PlexusDx compounded semaglutide injection is prepared by licensed 503A compounding pharmacies and available to people with Type 1 diabetes in all 50 states without insurance requirements. The medication starts at $149 per month across a flat-rate pricing structure, meaning your dose may increase as you progress through treatment, but your monthly cost remains the same. This transparent pricing removes barriers to accessing semaglutide therapy while you work with your diabetes care team on insulin adjustments.
PlexusDx also offers the Precision Peptide Genetic Test ($99 add-on after your first month), which maps 14 metabolic pathways and analyzes genetic variants affecting GLP-1 and GLP-1 receptor responsiveness. Understanding your genetic predispositions to peptide sensitivity can help your provider anticipate your likely response to semaglutide and optimize your treatment plan earlier. For Type 1 diabetes patients, this personalization can inform insulin reduction schedules and expected weight loss timelines.
Monitoring and Medical Coordination
Effective semaglutide use in Type 1 diabetes requires coordinated care: your diabetes specialist manages insulin, your primary care doctor oversees semaglutide therapy, and you monitor blood glucose frequently during the first 8 weeks of treatment. Most experts recommend continuous glucose monitoring (CGM) or frequent capillary testing to catch emerging hypoglycemia patterns as appetite and weight change. Written communication between your providers ensures insulin doses are reduced in a planned, safe manner rather than reactively.
Track your weight weekly, record your total daily insulin doses, and note any changes in hypoglycemia frequency or severity as semaglutide takes effect. Bring this data to your endocrinology appointments so adjustments can be made confidently and systematically. Your provider may suggest reducing basal insulin by 10–20 percent initially, then further reductions based on your blood sugar patterns and weight progress.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I use semaglutide if I have Type 1 diabetes?
Yes, but only under close medical supervision with your endocrinologist. Semaglutide reduces appetite and supports weight loss in Type 1 diabetes, but it does not replace insulin and requires careful insulin dose adjustment to prevent hypoglycemia. PlexusDx requires confirmation from your healthcare provider before dispensing semaglutide if you have Type 1 diabetes.
Will semaglutide lower my blood sugar in Type 1 diabetes?
Semaglutide does not directly lower blood sugar—it works by reducing appetite and supporting weight loss, which may improve your insulin sensitivity and reduce daily insulin requirements. As you lose weight and your tissue insulin sensitivity improves, your endocrinologist will reduce your insulin doses accordingly to maintain safe blood glucose levels. This is why insulin coordination is absolutely essential.
How much weight can I expect to lose with semaglutide and Type 1 diabetes?
Clinical data shows average weight losses of 8–15 pounds over 6 months in Type 1 diabetes patients using GLP-1 therapy, with some individuals losing more depending on baseline weight and adherence. Your individual response depends on genetic factors, diet, physical activity, and insulin management. PlexusDx Precision Peptide Genetic Testing can help predict your likely response based on GLP-1 receptor and metabolic pathway variants.
What are the main side effects of semaglutide in Type 1 diabetes?
Nausea, vomiting, constipation, and reduced appetite are most common, affecting 20–30 percent of users in the first 4–8 weeks. The serious risk in Type 1 diabetes is hypoglycemia if insulin doses are not reduced as appetite and weight decrease. Starting with a lower dose and titrating gradually minimizes side effects and gives your provider time to adjust insulin safely.
How does PlexusDx Precision Peptide Genetic Testing help with Type 1 diabetes and semaglutide?
The Precision Peptide Genetic Test ($99 add-on) analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence your response to GLP-1 receptor agonists and metabolic regulation. For Type 1 diabetes patients, understanding these genetic predispositions helps your provider anticipate your weight loss trajectory, optimize semaglutide titration speed, and coordinate insulin reductions more confidently.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Thyroid Health and Weight Management: Can Someone with Thyroid Problems Take Ozempic?
What All Does Ozempic Help With: More Than Just Weight Loss